POSITIVE TOPLINE DATA ANNOUNCED

A Phase 3 Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC

A Phase 1/2 trial in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab) in RCC

30th Annual Piper Jaffray Healthcare Conference
Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time.

AVEO TIVO-3 Topline Data Conference Call
Monday, November 5, 2018 at 5:00 p.m. Eastern Time

Leerink Partners Roundtable Series: Rare Disease & Oncology
Wednesday, October 3, 2018 at 1:00 p.m. Eastern Time

AVEO Oncology Announces Immuno-Oncology Clinical Collaboration with AstraZeneca
December 12, 2018

AVEO Oncology Announces Extension of Debt Facility Interest Only Period
December 4, 2018

AVEO Oncology to Present at the 30th Annual Piper Jaffray Healthcare Conference
November 20, 2018